- $2.25m
- -$3.19m
- $0.07m
Brief: Silo Pharma Partners With AmplifyBio To Advance SPC-15 For PTSD And Anxiety
Brief: Silo Pharma Announces Successful Production of its SP-26 Ketamine Implant for Fibromyalgia
Brief: Silo Pharma Announces $2 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
Brief: Silo Pharma Submits Pre-Investigational New Drug Application to FDA for SPC-15 as a Treatment for PTSD and Anxiety
Brief: Silo Pharma Announces Positive Results From Study For Depression Treatment, Remission, And Relapse Prevention
Brief: Silo Pharma Announces Positive Results for Intranasal PTSD Treatment
Brief: Silo Pharma Set To Acquire Exclusive Licensing For Alzheimer’s Disease Therapeutic From Columbia University
Brief: Silo Pharma Approves Extension Of Previously Announced Stock Repurchase Program
U.S. STOCKS ON THE MOVE-Micron, US hotels, Exxon Mobil
U.S. STOCKS ON THE MOVE-Micron, US hotels, Exxon Mobil
U.S. STOCKS ON THE MOVE-Nvidia, Tesla, Xpeng
Silo Pharma rises on filing patent application for ketamine-based implant
Brief: Silo Pharma Files Patent For Groundbreaking Ketamine Implant Therapeutic To Target Fibromyalgia And Chronic Pain
Brief: Silo Pharma Completes Successful Dose-Ranging Study of SPC-15 Intranasal Therapeutic for PTSD
Silo Pharma rises on positive data for its Alzheimer's disease therapy
Brief: Silo Pharma Announces Positive Results In Alzheimer’S Disease Study
U.S. STOCKS ON THE MOVE-Exxon Mobil, Energy Fuels, Barrick Gold
U.S. STOCKS ON THE MOVE-NeuroBo Pharma, EOG Resources, Nova LifeStyle
Silo Pharma up on nod to develop ketamine-based implants for pain disorder